Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Vir Biotechnology's selling, general, & admin. expense for the
three
months ended in Jun. 2026 was MXN527 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was MXN1,781 Mil.
Vir Biotechnology (MEX:VIR) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Vir Biotechnology Selling, General, & Admin. Expense Related Terms
Vir Biotechnology Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Vir Biotechnology's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology Selling, General, & Admin. Expense Chart
MEX:VIR vs AVBP, XNCR, SEPN: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, Vir Biotechnology's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's Selling, General, & Admin. Expense falls into.
Vir Biotechnology Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,781 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of MXN1,781 Mil mean?
Vir Biotechnology (MEX:VIR) has a Selling, General, & Admin. Expense of MXN1,781 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Vir Biotechnology and its competitors.
Is Vir Biotechnology's Selling, General, & Admin. Expense too high?
Vir Biotechnology's current Selling, General, & Admin. Expense is MXN1,781 Mil. Overall, Vir Biotechnology has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's Selling, General, & Admin. Expense compare to AVBP and XNCR?
Vir Biotechnology's Selling, General, & Admin. Expense of MXN1,781 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Vir Biotechnology and its competitors. Vir Biotechnology's current Selling, General, & Admin. Expense is MXN1,781 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Vir Biotechnology (MEX:VIR) has a current Selling, General, & Admin. Expense of MXN1,781 Mil. The stock's GF Value™ is MXN755.16, compared to a current price of MXN170.00 — trading 77.5% below its estimated fair value. The current Selling, General, & Admin. Expense is MXN1,781 Mil. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Vir Biotechnology (MEX:VIR), the current Selling, General, & Admin. Expense is MXN1,781 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (MEX:VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of MXN170.00 is trading 77.5% below its estimated GF Value™ of MXN755.16.
Key valuation signals for MEX:VIR:
Selling, General, & Admin. Expense: MXN1,781 Mil
GF Value™: MXN755.16 vs. price of MXN170.00 (77.5% below fair value)
No single metric tells the full story. See the MEX:VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for MEX:VIR
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VIR has been successfully added to your 
